Results 141 to 150 of about 746,801 (362)

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology

British Journal of Pharmacology, EarlyView.
Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller, Gary Gudelsky, T. John Winhusen, Davide Amato   +3 more
wiley   +1 more source

The amino terminal domain of the human α7 nicotinic acetylcholine receptor subunit leads to the functional expression of human/insect receptors

British Journal of Pharmacology, EarlyView.
Human α7 receptors have been characterised in terms of pharmacological properties. Insertion of the N‐terminal domain of the human α7 subunit leads to honeybee and cockroach chimeric receptors activated by ACh and inhibited by α‐Bgt. Insertion of the human cys‐loop leads to cockroach chimeric receptors modulated by PNU.
Alison Cartereau, Chloé Veront, Alexandra Cremades, Priscilla Martin, Remi Gojard, Nicolas Galland, Emiliane Taillebois, Dieudonnée Togbé, Jean‐Yves Le Questel, Steeve H. Thany   +9 more
wiley   +1 more source

Three‐year outcomes of repeated botulinum neurotoxin A injections to the lower extremities in young children with spastic cerebral palsy in GMFCS levels I to III

Developmental Medicine &Child Neurology, EarlyView.
In this study, we followed a group of children 2 to 6 years old with spastic cerebral palsy functioning in GMFCS levels I–III, over 3 years. Sixty‐five received BoNT‐A and 59 did not. Repeated BoNT‐A injections over 3 years were not associated with improvements in gross motor function or passive ankle dorsiflexion. Daily step counts, favouring the BoNT‐
Darcy Fehlings, Emma Bohn, Lauren Switzer, Charles H. Goldsmith, Unni Narayanan, Peter L. Rosenbaum, F. Virginia Wright, Gary Foster, CP‐BoNT‐A Study Group, Timothy Carey, Mark Mason, Ronit Mesterman   +11 more
wiley   +1 more source

Cerebral protective effects of eptazocme an opiate-antagonistic analgesic: A possible involvement of central cholinergic system

, 1988
T Tamura, Toshietsu Taniguchi, Masaru Aoki, Yukio MINAMI, Isami Waki   +4 more
openalex   +1 more source

Effects of α2-adrenergic receptor agonist and antagonist drugs on cholinergic contraction in bovine tracheal smooth muscle in vitro [PDF]

, 1995
Melanie M. Manning, Richard V. Broadstone   +1 more
openalex   +1 more source

Analgesic effects of alpha‐2‐adrenoreceptor agonists in equine medicine: systemic, spinal, and local applications

Equine Veterinary Education, EarlyView.
Summary Alpha‐2‐adrenoreceptor agonists provide analgesia when used as sole agents but can also be used in combination with other drugs for their additive and potentially synergistic effects. Further, because of their effects on blood flow, alpha‐2‐adrenoreceptor agonists act to extend and perhaps intensify the effects of drugs, such as local ...
J. Brandly, J. R. Page, J. A. E. Hubbell, W. W. Muir III, K. Hopster   +4 more
wiley   +1 more source

5-HT2A receptor enhancement of contractile activity of the porcine urothelium and lamina propria [PDF]

, 2016
Alexander, Andersson, Baxter, Berger, Birder, Blakeman, Blanco, Bschleipfer, Chapple, Gillespie, Ikeda, Imamura, Kanai, Lecci, Liang, Masunaga, Matsumoto-Miyai, Moro, Moro, Moro, Moro, Pfeiffer, Rahnama'i, Rahnama'i, Recio, Rekik, Sadananda, Sellers, Sleight, Wang   +29 more
core   +1 more source

Cholinergic Modulation of Locomotion and Striatal Dopamine Release Is Mediated by α6α4* Nicotinic Acetylcholine Receptors [PDF]

, 2010
Dopamine (DA) release in striatum is governed by firing rates of midbrain DA neurons, striatal cholinergic tone, and nicotinic ACh receptors (nAChRs) on DA presynaptic terminals.
Drenan, Ryan M., Grady, Sharon R., Lester, Henry A., Marks, Michael J., McIntosh, J. Michael, McKinney, Sheri, Miwa, Julie M., Patzlaff, Natalie E., Steele, Andrew D.   +8 more
core  

Evolving treatments for Sjögren disease: current approaches and emerging targets

Internal Medicine Journal, EarlyView.
Abstract Sjögren disease (SjD) is a prevalent systemic autoimmune condition characterised by exocrine gland dysfunction, systemic inflammation and heterogeneous organ involvement. Current management remains largely symptomatic, with no approved disease‐modifying therapies available and substantial unmet clinical need. However, advances in understanding
Mansi Bhurani, Adrian Y. S. Lee, Maureen Rischmueller, Alberta Hoi   +3 more
wiley   +1 more source

Gestational kynurenine metabolites mediate effects of pregnancy adiposity on child negative affect

Journal of Child Psychology and Psychiatry, EarlyView.
Background Mounting evidence links increased adiposity during pregnancy and offspring risk for mental health disorders. Yet the mechanisms underlying this association remain poorly understood, limiting our ability to design effective interventions.
Hanna C. Gustafsson, Hanna R. Wright, Jorden E. Jacinto Schreeder, Joel T. Nigg, Elinor L. Sullivan   +4 more
wiley   +1 more source